Little is known about the epidemiology and the management of liver metastases from colorectal cancer at a population level.
Dr Sylvain Manfredi and colleagues conducted a population-based study to evaluate the incidence, treatment, and prognosis of synchronous and metachronous liver metastases.
The investigative team obtained data from the population-based cancer registry of Burgundy in France.
The proportion of patients with synchronous liver metastases was 15%.
Age-standardized incidence rates were 7 per 100,000 in males, 4 per 100,000 in females.
The researchers found that the 5-year cumulative metachronous liver metastasis rate was 15%.
The team noted that it was 4% for TNM stage I tumors, 13% for stage II, and 30% for stage III.
|The 1-year survival rates for synchronous liver metastases was 35%|
|Annals of Surgery|
The risk of liver metastasis was also associated to gross features.
Resection for cure was performed in 6% of synchronous liver metastases, and 17% of metachronous liver metastases.
Age, presence of another site of recurrence, and period of diagnosis were independent factors associated with the performance of a resection for cure.
The team found that the 1- and 5-year survival rates were 35% and 3% for synchronous liver metastases.
Their corresponding rates for metachronous liver metastases were, 38% and 6%, respectively.
Dr Manfredi's team concludes, “Liver metastases from colorectal cancer remain a substantial problem.”
“More effective treatments and mass screening represent promising approaches to decrease this problem.”